WIKIMEDIA, PLOS BIOLOGYAn experimental Ebola serum that was given to some patients during the ongoing Ebola outbreak in West Africa “exceeds the efficacy of any other therapeutics described so far,” an international team led by investigators at the Public Health Agency of Canada reported in Nature last week (August 29). In a study on 19 Ebola-infected macaques, Mapp Biopharmaceutical’s monoclonal antibody cocktail ZMapp rescued all of the animals when treatment was initiated within five days post-infection, when they’d already reached an advanced disease stage.
“To actually be able to reverse all those symptoms and signs and bring them back to baseline, I think that is pretty astounding,” Kartik Chandran of the Albert Einstein College of Medicine who was not involved in the study told The New York Times. “If you are going to give somebody something during this outbreak, this would be it.”
Unfortunately, while the therapeutic has...
Interested in reading more?
The Scientist ARCHIVES
Become a Member of
